MX2023003169A - Composiciones de vacunas multivalentes y usos de las mismas. - Google Patents
Composiciones de vacunas multivalentes y usos de las mismas.Info
- Publication number
- MX2023003169A MX2023003169A MX2023003169A MX2023003169A MX2023003169A MX 2023003169 A MX2023003169 A MX 2023003169A MX 2023003169 A MX2023003169 A MX 2023003169A MX 2023003169 A MX2023003169 A MX 2023003169A MX 2023003169 A MX2023003169 A MX 2023003169A
- Authority
- MX
- Mexico
- Prior art keywords
- expec
- vaccine compositions
- compositions
- multivalent vaccine
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 241000588724 Escherichia coli Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen composiciones y métodos para inducir una respuesta inmunitaria contra la Escherichia coli patógena extraintestinal (ExPEC) para proporcionar de este modo una protección inmunitaria contra las enfermedades asociadas a la ExPEC. En particular, se describen composiciones y métodos para utilizar conjugados del polisacárido de antígeno O75 de E. coli unidos de manera covalente a una proteína portadora para la prevención de la enfermedad invasiva por ExPEC.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063079734P | 2020-09-17 | 2020-09-17 | |
EP21154782 | 2021-02-02 | ||
US202163191471P | 2021-05-21 | 2021-05-21 | |
PCT/IB2021/058485 WO2022058945A1 (en) | 2020-09-17 | 2021-09-17 | Multivalent vaccine compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003169A true MX2023003169A (es) | 2023-03-27 |
Family
ID=77801756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003169A MX2023003169A (es) | 2020-09-17 | 2021-09-17 | Composiciones de vacunas multivalentes y usos de las mismas. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220088165A1 (es) |
EP (1) | EP4213870A1 (es) |
JP (1) | JP7481585B2 (es) |
KR (1) | KR20230043157A (es) |
CN (1) | CN115803087A (es) |
AU (1) | AU2021342797B2 (es) |
BR (1) | BR112023004819A2 (es) |
CA (1) | CA3190820A1 (es) |
CL (1) | CL2023000740A1 (es) |
CO (1) | CO2023002114A2 (es) |
EC (1) | ECSP23019295A (es) |
IL (2) | IL301248B2 (es) |
MX (1) | MX2023003169A (es) |
PE (1) | PE20231385A1 (es) |
TW (1) | TW202227128A (es) |
UY (1) | UY39428A (es) |
WO (1) | WO2022058945A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
JOP20210256A1 (ar) | 2019-03-18 | 2023-01-30 | Janssen Pharmaceuticals Inc | متقارن حيوي لعديدات سكاريد المستضدات-o للإشريكية القولونية، طرائق إنتاجه، وطرائق استخدامه |
WO2024107729A2 (en) * | 2022-11-15 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
WO2024146325A1 (zh) * | 2023-01-06 | 2024-07-11 | 中国人民解放军军事科学院军事医学研究院 | 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
EP0911036A3 (en) | 1992-02-11 | 2001-05-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
EP0616034B1 (en) | 1993-03-05 | 2004-10-20 | Wyeth Holdings Corporation | Plasmid for production of CRM protein and diphtheria toxin |
NZ274376A (en) | 1993-09-22 | 1997-11-24 | Jackson H M Found Military Med | Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs |
NZ304715A (en) | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
KR100603884B1 (ko) | 1997-04-01 | 2006-07-24 | 코리사 코퍼레이션 | 모노포스포릴 지질 a의 수성 면역적 아쥬반트 조성물 |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
PL201482B1 (pl) | 1998-10-16 | 2009-04-30 | Smithkline Beecham Biolog | Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki |
ATE398463T1 (de) | 2000-04-13 | 2008-07-15 | Corixa Corp | Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten |
US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
EP1481057B1 (en) | 2002-03-07 | 2006-02-15 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
ES2703061T3 (es) | 2005-05-11 | 2019-03-06 | Eth Zuerich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
ES2388556T3 (es) | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
KR20100123730A (ko) | 2008-02-20 | 2010-11-24 | 글리코박신 아게 | 원핵생물 세포로부터의 n-당화된 재조합 단백질로부터 제조된 바이오컨쥬게이트 |
DK2437753T3 (en) | 2009-06-05 | 2016-12-19 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
CN104661684B (zh) | 2012-08-16 | 2018-03-20 | 辉瑞公司 | 糖缀合方法和组合物 |
CA2883000A1 (en) | 2012-09-10 | 2014-03-13 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
CN104837984A (zh) | 2012-10-12 | 2015-08-12 | 格林考瓦因有限公司 | 宿主细胞修饰方法 |
DK3363806T3 (da) | 2012-12-20 | 2022-11-21 | Pfizer | Glycokonjugationsfremgangsmåde |
SG11201508273RA (en) | 2013-05-18 | 2015-12-30 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
CA2926523C (en) | 2013-10-11 | 2023-09-26 | Glycovaxyn Ag | Methods of host cell modification |
EP3076998A1 (en) | 2013-12-04 | 2016-10-12 | Glycovaxyn AG | Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli |
CN106535927B (zh) | 2014-02-24 | 2019-09-20 | 葛兰素史密丝克莱恩生物有限公司 | 新颖多糖及其用途 |
SI3131577T1 (sl) | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
HUE057726T2 (hu) | 2014-12-30 | 2022-06-28 | Glaxosmithkline Biologicals Sa | Fehérje glikozilálására szolgáló készítmények és módszerek |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
US11260119B2 (en) * | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CN113227125A (zh) | 2018-12-12 | 2021-08-06 | 葛兰素史密丝克莱恩生物有限公司 | 用于o-连接的糖基化的修饰的载体蛋白 |
AR118389A1 (es) * | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
JOP20210256A1 (ar) * | 2019-03-18 | 2023-01-30 | Janssen Pharmaceuticals Inc | متقارن حيوي لعديدات سكاريد المستضدات-o للإشريكية القولونية، طرائق إنتاجه، وطرائق استخدامه |
MX2023011697A (es) * | 2021-04-01 | 2023-10-19 | Janssen Pharmaceuticals Inc | Produccion de bioconjugados o18 de e. coli. |
-
2021
- 2021-09-17 EP EP21772844.3A patent/EP4213870A1/en active Pending
- 2021-09-17 CN CN202180049038.6A patent/CN115803087A/zh active Pending
- 2021-09-17 MX MX2023003169A patent/MX2023003169A/es unknown
- 2021-09-17 TW TW110135002A patent/TW202227128A/zh unknown
- 2021-09-17 US US17/478,584 patent/US20220088165A1/en active Pending
- 2021-09-17 WO PCT/IB2021/058485 patent/WO2022058945A1/en active Application Filing
- 2021-09-17 JP JP2023517329A patent/JP7481585B2/ja active Active
- 2021-09-17 BR BR112023004819A patent/BR112023004819A2/pt unknown
- 2021-09-17 PE PE2023001175A patent/PE20231385A1/es unknown
- 2021-09-17 KR KR1020237006127A patent/KR20230043157A/ko active Search and Examination
- 2021-09-17 UY UY0001039428A patent/UY39428A/es unknown
- 2021-09-17 IL IL301248A patent/IL301248B2/en unknown
- 2021-09-17 AU AU2021342797A patent/AU2021342797B2/en active Active
- 2021-09-17 CA CA3190820A patent/CA3190820A1/en active Pending
- 2021-09-17 IL IL308201A patent/IL308201A/en unknown
-
2023
- 2023-02-27 CO CONC2023/0002114A patent/CO2023002114A2/es unknown
- 2023-03-15 CL CL2023000740A patent/CL2023000740A1/es unknown
- 2023-03-17 EC ECSENADI202319295A patent/ECSP23019295A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231385A1 (es) | 2023-09-12 |
ECSP23019295A (es) | 2023-04-28 |
IL301248B1 (en) | 2023-12-01 |
UY39428A (es) | 2022-03-31 |
IL301248B2 (en) | 2024-04-01 |
WO2022058945A1 (en) | 2022-03-24 |
IL308201A (en) | 2024-01-01 |
JP7481585B2 (ja) | 2024-05-10 |
IL301248A (en) | 2023-05-01 |
CO2023002114A2 (es) | 2023-03-07 |
CN115803087A (zh) | 2023-03-14 |
CA3190820A1 (en) | 2022-03-24 |
KR20230043157A (ko) | 2023-03-30 |
AU2021342797A1 (en) | 2023-02-16 |
AU2021342797B2 (en) | 2024-02-08 |
JP2023539943A (ja) | 2023-09-20 |
CL2023000740A1 (es) | 2023-09-29 |
EP4213870A1 (en) | 2023-07-26 |
BR112023004819A2 (pt) | 2023-04-18 |
US20220088165A1 (en) | 2022-03-24 |
TW202227128A (zh) | 2022-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003169A (es) | Composiciones de vacunas multivalentes y usos de las mismas. | |
EP4245320A3 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
Pan et al. | Biosynthesis of Self‐Assembled Proteinaceous Nanoparticles for Vaccination | |
PH12019500672A1 (en) | Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates | |
EA035991B9 (ru) | Новый полисахарид и его применения | |
MX2023004834A (es) | Formulaciones de vacunas de glicoconjugados de expec. | |
FI3583947T3 (fi) | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit | |
BR0314373A (pt) | Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
AU2020240075A8 (en) | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof | |
CL2022001196A1 (es) | Conjugados anticuerpo-fármaco dirigidos a la claudina 18.2 | |
Cryz Jr et al. | Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine | |
Dhakal et al. | Over-expression of gene encoding heat shock protein 70 from Mycobacterium tuberculosis and its evaluation as vaccine adjuvant | |
Faezi et al. | High yield overexpression, refolding, purification and characterization of Pseudomonas aeruginosa type B-flagellin: an improved method without sonication | |
Fischer et al. | Recombinant Escherichia coli heat-labile enterotoxin B subunit humoral adjuvant effect depends on dose and administration route | |
WO2024107729A3 (en) | Multivalent vaccine compositions and uses thereof | |
RU2015125699A (ru) | Антигены и комбинации антигенов pseudomonas | |
ES2336417T3 (es) | Proteinas del estres de patogenos extracelulares como vacunas contra agentes infecciosos. | |
Tanomand et al. | Protective properties of nontoxic recombinant exotoxin A (domain I-II) against Pseudomonas aeruginosa infection | |
MX2021015155A (es) | Polisacaridos de ramnosa. | |
Shyam et al. | Protective efficacy of calcium phosphate nanoparticle adsorbed bivalent subunit vaccine of pasteurella multocida against homologous challenge in mice | |
MX2009011495A (es) | V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad. | |
AR123545A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
MX2022001937A (es) | Composicion inmunogenica. | |
ES2549702B1 (es) | Proteína recombinante del receptor de la ferri-piscibactina y su aplicación para la producción de una composición inmunogénica frente a la pasteurelosis | |
MX2022015860A (es) | Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas. |